Pancragen is a synthetic tetrapeptide (four amino acids: Lys-Glu-Asp-Trp) classified as a peptide bioregulator. It is designed to target pancreatic tissue and has been studied for its effects on blood sugar regulation and pancreatic cell health. It is a research compound only — not a drug or supplement approved for human therapeutic use.[4]

How does Pancragen work?

Research suggests Pancragen works by stimulating the expression of differentiation factors inside pancreatic cells — essentially helping aging cells remember how to do their specialized jobs properly. This effect was seen in both insulin-producing islet cells and digestive enzyme-producing acinar cells, and was stronger in older cell cultures than younger ones.[4][6]

What is Pancragen used for in research?

Scientists have studied Pancragen for correcting age-related impaired glucose tolerance, reducing insulin resistance in elderly individuals with type 2 diabetes, lowering blood glucose in experimental diabetes models, and protecting capillary endothelium from diabetic damage. Studies span cell cultures, rat models, primate models, and observational human research.[1][2][3][5]

How is Pancragen dosed in research studies?

Published studies have consistently used very low doses — around 0.05 mg per day — over 10-day courses, via oral or intramuscular routes depending on the protocol.[1][3][5] Full details for each study context are in the dosage chart on this page. These figures are for research reference only and do not constitute medical dosing advice.

How do you reconstitute Pancragen?

Pancragen powder is typically dissolved in bacteriostatic water or sterile saline for research use. Add the liquid slowly along the vial wall and swirl gently — never shake. Because doses are measured in micrograms, precise low-volume measurement tools are essential. Store reconstituted solution refrigerated (2–8 °C) and use within a few weeks; keep unused dry powder frozen and light-protected.

Is Pancragen safe, based on available research?

In the studies reviewed, Pancragen appeared well tolerated in primate and human observational contexts, with researchers describing it as 'effective and safe' for correcting age-related pancreatic imbalance in elderly primates.[3] However, the research base is still limited, it is not an approved medicine, and no conclusions about human safety can be drawn from these early studies. Always consult qualified professionals before any research application.

Pancragen Dosage Chart, Protocol & Calculator

A pancreas peptide bioregulator studied for metabolism.

Goal	Dose	Frequency	Duration	Evidence	Source
Correction of age-related impaired glucose tolerance / endocrine pancreatic dysfunction (primate model)	0.05 mg	1x/day	10 days	Preclinical	PMID 28509500 PMID 25946840
Correction of insulin resistance and metabolic disorders in elderly patients with type 2 diabetes mellitus	0.05 mg	1x/day	10 days	Clinical	PMID 22448364
Hypoglycemic effect in experimental streptozotocin-induced diabetes mellitus (rat model) - oral route	0.05 mg	1x/day	per trial	Preclinical	PMID 18642713
Endothelioprotective and capillary adhesion normalization in experimental diabetes mellitus (rat model) - intramuscular route	0.05 mg	1x/day	per trial	Preclinical	PMID 18642713

What is Pancragen?

Pancragen is a short synthetic peptide — just four amino acids long (Lys-Glu-Asp-Trp, sometimes written with an amide at the end). That makes it a tetrapeptide. It belongs to a family of compounds called peptide bioregulators: tiny signaling molecules designed to mimic the natural peptides your body uses to keep specific organs running smoothly. As the name hints, Pancragen targets the pancreas — the gland that produces insulin and digestive enzymes. It is a research compound only, not approved as a medicine, and everything on this page describes laboratory and preclinical findings.

How Pancragen Works

Think of your pancreas cells like workers in a factory. When you're young, those workers follow their instructions perfectly — producing just the right amount of insulin at just the right time. As the body ages, the instruction manual gets harder to read, and the workers start making mistakes. Pancragen appears to act like a fresh copy of that manual.

In lab cell cultures, researchers found that the markers of healthy cell differentiation (the biological word for cells doing their specific, specialized jobs) drop off as cells age. When Pancragen was added, expression of key differentiation factors — including Pdx1, Pax6, Pax4, Foxa2, and NKx2.2 for islet (insulin-producing) cells, and Pdx1 and Ptf1a for acinar (digestive enzyme) cells — went back up.^[4] Importantly, the effect was stronger in older cells than in younger ones, which is exactly the behavior you'd want from an age-targeting compound.^[6] Researchers suggest this cell-level rejuvenation of pancreatic tissue could be the mechanism behind Pancragen's observed metabolic effects.

What the Research Shows

Primate studies

Old female rhesus monkeys (aged 20–25 years — elderly by primate standards) showed the classic sign of metabolic aging: impaired glucose tolerance, meaning their blood sugar stayed elevated too long after eating. After a 10-day course of Pancragen, glucose clearance improved markedly, and plasma insulin and C-peptide levels (both markers of how well the pancreas is responding) normalized. Crucially, some of the improvement was still measurable three weeks after the peptide was stopped.^[5] A follow-up study compared Pancragen directly to glimepiride, a widely-used diabetes drug. Both lowered fasting blood glucose, but Pancragen also normalized insulin and C-peptide secretion together — suggesting a more balanced, regulatory effect rather than simply forcing more insulin out.^[3]

Human clinical observation

A study in Ukraine looked at two groups of older adults: 30 healthy individuals and 33 patients with type 2 diabetes mellitus. People with type 2 diabetes had about 70% lower nighttime melatonin levels compared to healthy age-matched peers — an interesting metabolic connection. In the diabetic group, Pancragen significantly reduced fasting blood glucose, improved glucose tolerance test results, and lowered both insulin levels and the insulin resistance index. No similar changes appeared in the group that did not receive Pancragen.^[1]

Rat diabetes model

In Wistar rats given streptozotocin (a chemical that destroys insulin-producing cells and creates a model of diabetes), Pancragen produced a clear blood-sugar-lowering effect when given orally.^[2] A separate route of administration — intramuscular injection — normalized the adhesion of cells lining the tiny capillaries in the gut (mesenteric capillaries), an effect called endothelioprotection. Damaged capillary endothelium is a known driver of diabetic complications, so this finding adds another dimension to Pancragen's potential profile.^[2]

Cell biology

Lab work on aging human embryonic pancreatic cells confirmed that Pancragen specifically boosts differentiation signaling factors (including CXCL12 and Hoxa3) in pancreatic tissue but not in unrelated cell types — evidence that its action is tissue-specific, not a blanket stimulus.^[6]

What Pancragen Is Being Studied For

Age-related decline in pancreatic endocrine function^[5]
Impaired glucose tolerance in older subjects^[3]
Insulin resistance and type 2 diabetes metabolic markers in elderly people^[1]
Blood glucose regulation in experimental (streptozotocin) diabetes models^[2]
Capillary endothelium health and adhesion in diabetic conditions^[2]
Cellular differentiation of pancreatic acinar and islet cells during aging^[4]

How Pancragen Is Dosed in Research

Across the studies summarized here, the dose used has been consistently small — on the order of micrograms per day, administered over short 10-day courses via oral, intramuscular, or subcutaneous routes depending on the protocol.^[1][2][3][5] Exact figures for each research context are laid out in the dosage chart on this page. If you need to scale or convert amounts for a specific research protocol, use the calculator tool available on this site. Remember: these are reference doses from published animal and observational human studies — not prescriptions or clinical guidelines.

Mixing and Storing Pancragen

Pancragen, like most research peptides, is typically supplied as a lyophilized powder (freeze-dried, white or off-white). To prepare it for use in a research setting, bacteriostatic water or sterile saline is slowly added to the vial — usually along the inner wall, not directly onto the powder, to avoid damaging the peptide structure. Swirl gently; never shake. Because the doses involved are very small (micrograms), accurate low-volume syringes and precise calculations are essential. Once reconstituted, store the solution in a refrigerator (2–8 °C) and use within a few weeks; keep the dry powder frozen and away from light until needed. Always check the supplier's certificate of analysis for purity before use in any research application.

Sources

Prospects of using pancragen for correction of metabolic disorders in elderly people. — Bulletin of experimental biology and medicine, 2011. PMID 22448364.
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. — Bulletin of experimental biology and medicine, 2007. PMID 18642713.
[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys]. — Advances in gerontology = Uspekhi gerontologii, 2015. PMID 28509500.
Effects of pancragen on the differentiation of pancreatic cells during their ageing. — Bulletin of experimental biology and medicine, 2013. PMID 23486591.
[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]. — Advances in gerontology = Uspekhi gerontologii, 2014. PMID 25946840.
Peptides tissue-specifically stimulate cell differentiation during their aging. — Bulletin of experimental biology and medicine, 2012. PMID 22808515.

Pancragen Guide & Dosage Chart